Updates are available Correction dated 2023-12-21

Article History

Accepted: 25 October 2023

First Online: 13 November 2023

Change Date: 21 December 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40266-023-01088-4

Declarations

:

: This research received no external funding.

: Éric Pautas has received honoraria for participating in expert meetings on dabigatran (from Boehringer Ingelheim), rivaroxaban (from Bayer Healthcare AG), apixaban (Bristol Myers Squibb-Pfizer), and warfarin (Merck). Théodore Decaix, Kenza Kemache, Pierre Gay, Olivier Laprévote, and Flora Ketz declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.

: The data presented in this study are available on request from the corresponding author.

: Study methodology corresponds to studies not involving human subjects (MR–004). The study was conducted in accordance with the Declaration of Helsinki and the database was declared to the French National Commission on Computing and Liberty (CNIL) of the Assistance Publique–Hôpitaux de Paris (APHP) for this study (no. 20230403102132).

: No subjects involved in this study objected to the retrospective processing of their data.

: Not applicable.

: Not applicable.

: Conceptualization, T.D., F.K. and E.P.; methodology, T.D., F.K. and E.P.; software, T.D.; validation, T.D., E.P.; formal analysis, T.D.; investigation, T.D., K.K., P.G.; resources, F.K., E.P.; data curation, F.K., E.P.; writing—original draft preparation, T.D., E.P.; writing—review and editing, T.D., K.K., O.L., F.K., and E.P.; visualization, T.D.; supervision, O.L., E.P.; project administration, E.P. All authors have read and agreed to the published version of the manuscript.